TABLE 1

Demographic and oncologic characteristics of controls and cases

Data are medians with interquartile ranges or percentages. Differences were analyzed by two-tailed Mann-Whitney test, Fisher exact test, or two-tailed χ2 test, as appropriate.

CharacteristicsControls (n = 51)Cases (n = 24)P Value
Age (n, %)0.090
 <40 yr9 (18%)2 (8%)
 40–60 yr36 (70%)18 (75%)
 >60 yr6 (12%)4 (17%)
Gender0.480
 Male9 (18%)3 (13%)
 Female42 (82%)21 (87%)
Oncologic disease0.480
 Breast cancer35 (69%)16 (67%)
 Non Hodgkin lymphoma10 (20%)6 (25%)
 Colorectal cancer6 (11%)2 (8%)
Chemotherapy0.844
 Anthracycline-baseda,b45 (88%)22 (92%)
 Nonanthracyclinec6 (12%)2 (8%)
Anthracycline dose (mg/m2)d240 (240–267)240 (240–291)0.844
  • a For breast cancer: doxorubicin (or epirubicin)-cyclophosphamide followed by a taxane, or epirubicin-cyclophosphamide-taxane, or fluorouracil-epirubicin-cyclophosphamide with or without a subsequent taxane.

  • b For non-Hodgkin lymphoma: rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone.

  • c For colorectal cancer: fluorouracil-folinate-oxaliplatinum, or capecitabine-oxaliplatinum.

  • d Expressed as doxorubicin myelotoxic equivalents.